Beckman Coulter/Princeton BioMeditech agreement
In a move that underscores its growing commitment to the market for rapid diagnostic medical test products, Beckman Coulter has entered into a supply relationship with Princeton BioMeditech (PBM). Under the agreement, PBM will supply a wide range of rapid diagnostic tools used at the point of medical care to Beckman Coulter's Primary Care Diagnostics business unit (PCD).
Princeton BioMeditech is a leading innovator and manufacturer of simple and rapid diagnostic products used at the point of care. The company offers more than 70 tests covering fertility management, infectious diseases, cardiac markers, drugs of abuse, cancer markers, environmental and veterinary diagnostics that enable consumers and professionals to improve speed and quality of diagnosis for better patient care.
Billion-dollar deal for UQ's molecular clamp vaccine tech
Sanofi has entered into an agreement to acquire Vicebio, a biotech company formed in 2018 to...
Director of scandal-ridden Forensic Science Queensland resigns
Dr Linzi Wilson-Wilde resigned from her position one month after being suspended by Queensland...
$492m pathology hub coming to Westmead Health Precinct
The NSW Health Pathology Statewide Hub will be delivered to Westmead Health Precinct, as part of...
